BBIO PDUFA decision: Thursday, February 4, 2027

…riority Review of NDA for Oral Infigratinib for Children with Achondroplasia   - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for childre

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.